Skip to Main Content

Print | Bookmark | Email | Font Size: + |

LCD / Medical Policies Stakeholder Meetings

Compliance Officer Meetings

Closed to members & invited guests

State Date/Time Location
J15 KY/OH February 13, 2024
2:30 – 3:30 PM ET
Microsoft Teams
J15 KY/OH June 18, 2024
2:30 – 3:30 PM ET
The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219
J15 KY October 29, 2024
2:30 – 3:30 PM ET
Norton Women's & Children's Hospital
Medical Plaza 1
Ground Floor, LLD Conference Room
3999 Dutchmans Lane
Louisville, KY 40207
J15 OH October 30, 2024
2:30 – 3:30 PM ET
OSU Wexner Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

Contractor Advisory Committee (CAC) Meetings

CAC meetings are for the purpose of discussing literature related to proposed Local Coverage Determinations (LCDs) before they're developed.

CAC members serve in an advisory capacity. All meetings are open to the public to attend and observe.

State Date/Time Location Agenda Documentation

Multi-Jurisdictional Host: National Government Services

October 17, 2024, 3-5 PM ET

Webex

RegistrationExternal Website

Topic: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)

 

Multi-Jurisdictional Host: Palmetto GBA

July 15, 2024
2-4 PM ET

Microsoft Teams

Topics: MolDX: Biomarker Risk Stratification Testing in DCIS

Transcript and RecordingsExternal Website

See Prior CAC Meetings below.

Open Meetings

Open Meetings are for the purpose of discussing new proposed (draft) LCDs and/or the revised portion of a proposed LCD in the 45-day open comment period. These meetings are not a forum to discuss specific claims, the submission of new drugs or indications, or to market forthcoming drugs or medical devices.

Open to the public

State Date/Time Location Agenda Documentation
J15 KY/OH February 13, 2024
4-5 PM ET
Microsoft Teams

Topics:

  • DL38773 – Facet Joint Interventions for Pain Management
  • DA58364 – Billing and Coding: Facet Joint Interventions for Pain Management
  • DL39741 – Cervical Fusion
  • DA59608 – Billing and Coding: Cervical Fusion

Proposed/Draft LCDs not released to final:

J15 KY/OH May 16, 2024
3-5 PM ET
Microsoft Teams

Topics:

  • DL39756/DA59618 – Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • DL39802/DA59682 – Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ)

Proposed/Draft LCDs not released to final:

J15 KY/OH June 18, 2024
4-5 PM ET
The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219 and Microsoft Teams

Topics:

  • DL37578/DA56491 – MIGS
  • DL39857/DA59726 – Botulinum Toxins
  • DL39840/DA59716 – Quantitative Coronary Plaque Analysis derived from Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QTC)/Coronary Plaque Analysis (AI-CPA)

Proposed/Draft LCDs not released to final:

J15 KY

October 29, 2024
4-5 PM ET

Marshall Women's Health & Education Center
4123 Dutchmans Lane
Medical Plaza 1
Ground Floor, LLD Conference Room
Louisville, KY 40207

and Microsoft Teams

To attend via Microsoft Teams, you must registerExternal Website.

Topics:

  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection (DL38582/DA58061)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)

Proposed/Draft LCDs not released to final:

J15 OH

October 30, 2024
4-5 PM ET

OSU Wexler Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

and Microsoft Teams

To attend via Microsoft Teams, you must registerExternal Website.

Topics:

  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection (DL38582/DA58061)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)

Proposed/Draft LCDs not released to final:

See Prior Open Meetings below.

Provider Touch Point Meetings

Closed to members & invited guests

State Date/Time Location
J15 KY/OH February 13, 2024
6 – 7 PM ET
Microsoft Teams
J15 KY/OH June 18, 2024
6 – 7 PM ET
The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219
J15 KY October 29, 2024
6 – 7 PM ET
Norton Women's & Children's Hospital
Medical Plaza 1
Ground Floor, LLD Conference Room
3999 Dutchmans Lane
Louisville, KY 40207
J15 OH October 30, 2024
6 – 7 PM ET
OSU Wexner Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

Prior CAC Meetings

Date Topic Details Documentation

10.19.2023

Botulinum Toxins

08.16.2023

Cervical Fusion

05.25.2023

Non-Invasive Technology for Coronary Artery Plaque Analysis

04.27.2023

Trigger Point Injections

  • Multi-Jurisdictional Host: WPS Government Health Administrators (GHA)

02.28.2023

RPM and RTM for Non-Implantable Devices

  • Multi-Jurisdictional Host: Novitas and First Coast Service Options

01.05.2023

Micro-Invasive Glaucoma Surgery (MIGS)

11.09.2022

PET Scans for Inflammation and Infection

03.10.2022

Sacroiliac Joint Injections and Procedures

12.07.2021

MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

10.12.2021

MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer

09.29.2021

Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)

05.12.2021

Amniotic Product Injections for Musculoskeletal Indications, Non-Wound

03.10.2021

Platelet Rich Plasma for Non-Wound Care

02.11.2021

Epidural Interventions for Chronic Pain Management

01.11.2021

Molecular Diagnostic Testing for Pathogens

11.18.2020

Electroretinography

 

05.28.2020

Facet Joint and Medical Nerve Branch Procedures

 

06.29.2019

Pharmacogenomics

 

03.20.2019

Vertebral Augmentation

 

Prior Open Meetings

State Date Topics Documentation
J15 OH 11.08.2023
  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)
J15 KY 11.07.2023
  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)
J15 KY/OH 07.11.2023
  • Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
  • Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)
  • Micro-Invasive Glaucoma Surgery (MIGS)MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
J15 KY/OH 06.22.2023

Urinary Biomarkers for Chronic Pain Management

J15 KY/OH 05.17.2023

Urine Drug Testing

J15 KY/OH 02.21.2023
  • Cosmetic and Reconstructive Surgery
  • Positron Emission Tomography (PET) for Inflammation and Infection Special Histochemical Stains and Immunohistochemical Stains
  • Transthoracic Echocardiography (TTE)
J15 OH 10.26.2022
  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing
J15 KY 10.25.2022
  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing
J15 KY/OH 06.21.2022
  • MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia and Neoplasia
  • MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
  • Prostate Cancer Detection with IsoPSA™
  • Transcranial Magnetic Stimulation (TMS)
J15 KY/OH 02.22.2022

Non-Invasive Fractional Flow Reserve (FFR) for Stable Ischemic Heart Disease

J15 KY/OH 10.13.2021
  • Colon Capsule Endoscopy (CCE)
  • Prostate Cancer Detection with IsoPSA™
J15 KY/OH 07.13.2021
  • Epidural Procedures for Pain Management
  • MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
  • MolDX: Melanoma Risk Stratification Molecular Testing
  • MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
J15 KY/OH 02.23.2021
  • Off-Label Use of Rituximab and Rituximab Biosimilars
  • Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)
J15 KY/OH 10.13.2020

Non-Invasive Flow Reserve (FFR) for Stable Ischemic Heart Disease

J15 KY/OH 10.13.2020
  • Colon Capsule Endoscopy (CCE)
  • Controlled Substance Monitoring and Drugs of Abuse Testing
  • Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the Treatment of Neurologic Conditions
  • MolDX: Minimal Residual Disease Testing (MRDT) for Cancer
J15 KY/OH 10.13.2020

Facet Joint Interventions for Pain Management

J15 KY/OH 02.18.2020

Vitamin D Assay Testing (L33996) Reconsideration

J15 OH 10.30.2019

Open Draft/Revised LCD Discussion

J15 KY 10.29.2019

Open Draft/Revised LCD Discussion

J15 KY/OH 06.18.2019

Open Draft/Revised LCD Discussion

J15 KY/OH 05.07.2019

Drug Interaction Testing and Multiple MolDX Draft Policies

J15 KY/OH 02.12.2019

MolDX: DecisionDx – Melanoma

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved